On June 8, 2018 the Honorable Roger W. Titus of the United States District Court for the District of Maryland certified a class of investors who purchased or otherwise acquired Emergent Biosolutions, Inc. common stock from May 5, 2016 through June 1, 2016. Daniel S. Bettencourt, Vice President of Crowninshield Financial Research, provided expert report about market efficiency and whether damages can be computed for the Class.

In particular, the Court noted “Bettencourt comes forth with sufficient evidence to show that both the event study and collective tests performed are accepted methods to test market efficiency and were reliably applied to the facts and theories of this case.”

Additional information is available here.